These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31828087)

  • 1. Plasma and Renal Cortex Meropenem Concentrations in Patients Undergoing Percutaneous Renal Biopsy.
    Sepúlveda RA; Downey P; Soto D; Wong KY; Leung YC; So LY; Andresen M
    Biomed Res Int; 2019; 2019():1368397. PubMed ID: 31828087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study.
    Eisert A; Lanckohr C; Frey J; Frey O; Wicha SG; Horn D; Ellger B; Schuerholz T; Marx G; Simon TP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106289. PubMed ID: 33515688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples.
    Al-Shaer MH; Alghamdi WA; Graham E; Peloquin CA
    Ther Drug Monit; 2020 Feb; 42(1):129-132. PubMed ID: 31318843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
    Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
    Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
    Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock.
    Taccone FS; Cotton F; Roisin S; Vincent JL; Jacobs F
    Antimicrob Agents Chemother; 2012 Apr; 56(4):2129-31. PubMed ID: 22290984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-Daily Plazomicin for Complicated Urinary Tract Infections.
    Wagenlehner FME; Cloutier DJ; Komirenko AS; Cebrik DS; Krause KM; Keepers TR; Connolly LE; Miller LG; Friedland I; Dwyer JP;
    N Engl J Med; 2019 Feb; 380(8):729-740. PubMed ID: 30786187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock.
    Karjagin J; Lefeuvre S; Oselin K; Kipper K; Marchand S; Tikkerberi A; Starkopf J; Couet W; Sawchuk RJ
    Clin Pharmacol Ther; 2008 Mar; 83(3):452-9. PubMed ID: 17687272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case-control study of drug monitoring of β-lactams in obese critically ill patients.
    Hites M; Taccone FS; Wolff F; Cotton F; Beumier M; De Backer D; Roisin S; Lorent S; Surin R; Seyler L; Vincent JL; Jacobs F
    Antimicrob Agents Chemother; 2013 Feb; 57(2):708-15. PubMed ID: 23147743
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and synovial fluid pharmacokinetics of a single intravenous dose of meropenem in adult horses.
    Langston VC; Fontenot RL; Byers JA; Andrews CM; Mochal-King CA
    J Vet Pharmacol Ther; 2019 Sep; 42(5):525-529. PubMed ID: 31222751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
    Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
    BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections.
    Kim YK; Lee DH; Jeon J; Jang HJ; Kim HK; Jin K; Lim SN; Lee SS; Park BS; Kim YW; Shin JG; Kiem S
    Clin Ther; 2018 Aug; 40(8):1384-1395. PubMed ID: 30093133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteremic Urinary Tract Infection Caused by Multidrug-Resistant Enterobacteriaceae Are Associated With Severe Sepsis at Admission: Implication for Empirical Therapy.
    Lee YC; Hsiao CY; Hung MC; Hung SC; Wang HP; Huang YJ; Wang JT
    Medicine (Baltimore); 2016 May; 95(20):e3694. PubMed ID: 27196480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.
    Schoenenberger-Arnaiz JA; Ahmad-Diaz F; Miralbes-Torner M; Aragones-Eroles A; Cano-Marron M; Palomar-Martinez M
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e30-e35. PubMed ID: 32296502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts.
    Hamanoue S; Suwabe T; Ubara Y; Kikuchi K; Hazue R; Mise K; Ueno T; Takaichi K; Matsumoto K; Morita K
    BMC Nephrol; 2018 Oct; 19(1):272. PubMed ID: 30340529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.